In 2006, Transition has completed a Canadian Phase I clinical trial for lead Alzheimer's product, ELND005 (AZD-103) [Link to News]. The objective of this trial was to evaluate the pharmacokinetics, safety and tolerability of escalating oral doses of ELND005 (AZD-103) in 12 healthy volunteers. Results from Canadian Phase I Clinical Trial showed that ELND005 (AZD-103) was well tolerated by all subjects.
ELND005 (AZD-103) is part of an emerging class of disease-modifying agents that have the potential to both reduce disease progression and improve symptoms such as cognitive function. ELND005 (AZD-103) breaks down neurotoxic fibrils, allowing amyloid peptides to clear the body rather than form amyloid plaques - a hallmark pathology of Alzheimer's disease.
In preclinical studies with animal models of Alzheimer's disease, ELND005 (AZD-103) has been shown to prevent disease onset as well as slow, stop and reverse disease progression. Further, ELND005 (AZD-103) is well positioned as an Alzheimer's therapy as it is taken orally, crosses the blood brain barrier and has an excellent safety profile.
In Morris water maze test (a well-accepted model for spatial memory function studies in which mice are required to find a platform in a shallow pool), ELND005 (AZD-103) improved the spatial memory function of AD mice to levels that were indistinguishable from normal healthy mice.
About Alzheimer's Disease
Alzheimer's disease is a progressive brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. The disease affects more than 4 million Americans and with an aging population is expected to double over the next 20 years unless an effective therapy is developed.